A recent SPECTRUM article discussed the FDA’s ‘breakthrough device’ designation for a hair-based diagnostic test for autism. The test is called StranDx, and it was developed by Linus Biotechnology Inc., a provider of precision exposome sequencing. StranDx analyzes the levels of chemicals in a child’s hair for a snapshot of their ‘exposome,’ which includes their environmental exposures and how they regulate certain essential nutrients. This sheds light on how a child’s physiology responds to their environment, which can predict the chances of autism.
FDA Grants ‘Breakthrough Device’ Status to Hair-Based Autism Test
The test analyzes chemical levels in a strand of a child’s hair to predict their chances of having autism.
Jan 21, 2022
Recommended
Recommended
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
